This is consistent with a study in bladder cancer, where knockdown of Cdk6 and SIRT-1 (direct targets of miR-34a) was not as effective reversing cisplatin resistance as miR-34a restoration[18]. The gene discussed is CDK6; the disease is urinary bladder cancer.